Vivozon
Vivozon is a global innovative drug development company established in 2008 in Yongin, South Korea. The company specializes in the discovery, development and commercialization of small molecule drugs for the treatment of central nervous system diseases and non-opioid pain management. Vivozon has developed a unique efficacy-based drug discovery system and has a pipeline of drug candidates, including the non-narcotic analgesic opiranserin (VVZ-149) which is in global phase 3 clinical trials. Industries it has a preference for include: Diversified/Conglomerates, Biotechnology, Healthcare Verticals it has a preference for include: PropTech.